XTL Biopharmaceuticals Ltd.
XTLB | TA
Overview
Corporate Details
- ISIN(s):
- IL0010854979
- LEI:
- 529900NDDXEAPTUTXP41
- Country:
- Israel
- Address:
- 5 HaCharoshet St., 4365603 Raanana
- Website:
- https://www.xtlbio.com
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of late-stage pharmaceutical product candidates. The company's strategy centers on advancing proprietary therapeutics to address unmet clinical needs, with a primary focus on the treatment of autoimmune diseases.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for XTL Biopharmaceuticals Ltd..
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-29 08:54 |
Foreign Filer Report
Immediate Report
|
English | 110.3 KB | |
| 2025-07-29 08:54 |
Foreign Filer Report
Immediate Report
|
English | 36.4 KB | |
| 2025-07-24 00:45 |
Pre-Annual General Meeting Information
Immediate Report
|
English | 112.7 KB | |
| 2025-07-24 00:45 |
Foreign Filer Report
Immediate Report
|
English | 36.4 KB | |
| 2025-06-15 11:36 |
Board/Management Information
Immediate Report of Meeting to be held on July 21, 2025
|
English | 735.8 KB | |
| 2025-06-15 11:36 |
Foreign Filer Report
Immediate Report of Meeting to be held on July 21, 2025
|
English | 262.4 KB | |
| 2025-06-15 11:36 |
Pre-Annual General Meeting Information
Immediate Report of Meeting to be held on July 21, 2025
|
English | 131.2 KB | |
| 2025-05-01 01:18 |
Foreign Filer Report
FORM 20-F For the fiscal year ended December 31, 2024
|
English | 5.4 MB | |
| 2025-05-01 01:18 |
Foreign Filer Report
FORM 20-F For the fiscal year ended December 31, 2024
|
English | 36.3 KB | |
| 2025-04-07 18:27 |
Board/Management Information
Noam Band was appointed the Chief Executive Officer, Mr. Band replaces Shlomo S…
|
English | 141.8 KB | |
| 2025-04-07 18:27 |
Foreign Filer Report
Noam Band was appointed the Chief Executive Officer, Mr. Band replaces Shlomo S…
|
English | 36.3 KB | |
| 2025-03-04 14:39 |
Foreign Filer Report
Definitive Exclusive Sublicense Agreement with Biossil, a company incorporated …
|
English | 116.4 KB | |
| 2025-03-04 14:39 |
Foreign Filer Report
Definitive Exclusive Sublicense Agreement with Biossil, a company incorporated …
|
English | 36.3 KB | |
| 2025-02-04 00:17 |
Foreign Filer Report
. Tal Klinger’s and Yair Redl’s decisions to resign from the Board were not due…
|
English | 111.2 KB | |
| 2025-02-04 00:17 |
Foreign Filer Report
. Tal Klinger’s and Yair Redl’s decisions to resign from the Board were not due…
|
English | 36.3 KB |
Automate Your Workflow. Get a real-time feed of all XTL Biopharmaceuticals Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for XTL Biopharmaceuticals Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
